Printer Friendly

HEAD STANFORD LAWYER JOHN SCHWARTZ JOINS SYSTEMIX

 PALO ALTO, Calif., Jan. 27 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX) today announced it has appointed former Stanford chief lawyer John J. Schwartz, J.D., Ph.D, as vice president and general counsel. Dr. Schwartz brings to the firm more than 30 years legal experience, much of it in the medical/legal and health care law fields.
 "John's unique background in physics and in law makes him a tremendous addition to our team. His expertise is especially important in today's climate of regulatory reform and evolving legal issues which are shaping the biotechnology industry," said Linda Sonntag, Ph.D., president and chief executive officer.
 Prior to joining SyStemix, Dr. Schwartz, 58, was vice president and general counsel at Stanford University. During his 20 years as counsel for medical affairs and general counsel at the university, Dr. Schwartz led Stanford through many key and controversial legal battles. In 1991, he played a critical role in a landmark court decision that prohibited the National Institute of Health (NIH), and other federal agencies, from requiring faculty researchers to submit articles for pre-publication approval by government project officers. Dr. Schwartz was also an assistant professor of physics at Stanford and the University of Rochester. Previously, he was a practicing tax law attorney in Phoenix, Arizona.
 "My association with Stanford was tremendously rewarding and I am remarkably fortunate to have the opportunity at SyStemix to be associated again with such outstanding science and leadership," said Dr. Schwartz.
 Dr. Schwartz received a J.D. from Harvard University and holds a Ph.D. in physics from the University of Rochester. He received his B.A. in physics from Cornell University.
 SyStemix, Inc., based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megakaryocyte progenitors.
 -0- 1/27/93
 /CONTACT: Linda Sonntag, Ph.D., president & CEO of SyStemix, Inc., 415-813-6510, or Anthony J. Russo, Ph.D., of Noonan/Russo Communications, Inc., 212-979-9180, for SyStemix/
 (STMX)


CO: SyStemix, Inc. ST: California IN: MTC SU: PER

TM -- NY008 -- 9438 01/27/93 08:30 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1993
Words:348
Previous Article:PRAXAIR REPORTS PRELIMINARY RESULTS AND PROFIT IMPROVEMENT INITIATIVE
Next Article:SYSTEMIX APPOINTS NATIONAL CANCER INSTITUTE SENIOR INVESTIGATOR AS DIRECTOR OF GENE THERAPY
Topics:


Related Articles
SYSTEMIX APPOINTS THREE SENIOR EXECUTIVES
SYSTEMIX MOVES TO STATE-OF-THE-ART FACILITY
SYSTEMIX APPOINTS NATIONAL CANCER INSTITUTE SENIOR INVESTIGATOR AS DIRECTOR OF GENE THERAPY
SYSTEMIX HIRES VICE PRESIDENT OF PRECLINICAL RESEARCH
SYSTEMIX APPOINTS NEW VICE PRESIDENT FOR MEDICAL AFFAIRS
SYSTEMIX REPORTS FIRST QUARTER RESULTS
SYSTEMIX REPORTS SECOND QUARTER RESULTS
SYSTEMIX REPORTS SECOND QUARTER RESULTS
SYSTEMIX PHASE I/II TRIAL OF PURIFIED BLOOD CELL TRANSPLANTS SHOWS PRELIMINARY RESULTS FOR CANCER PATIENTS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters